glp-1 drug least chemical modification glp-1_analogs [TUSOM Science Behind GLP 1 GIP

Accessed November 11, 2023

They were randomly assigned to receive different doses of Retatrutide or a placebo over 48 weeks

Where Injected GLP-1 Therapies Still Lead Weekly injections such as Wegovy and Mounjaro remain ahead in: Higher average long-term weight-loss percentages More established long-term safety data Real-world evidence across large patient populations Because injections have been studied for over a decade, they currently hold the strongest clinical outcomes in obesity care

Neumiller JJ, White JR, Campbell RK

A study from the Employee Benefit Research Institute (EBRI), supported by the Blue Cross Blue Shield Association and other partners, estimates that GLP-1 coverage would be a major premium driver for employer-provided coverage